Patents Assigned to AMAG Pharmaceuticals, Inc.
-
Patent number: 10556922Abstract: The disclosure is in part directed to crystalline forms of 17-?-hydroxyprogesterone caproate and variants thereof.Type: GrantFiled: September 29, 2016Date of Patent: February 11, 2020Assignee: AMAG PHARMACEUTICALS, INC.Inventor: Mahmoud Mirmehrabi
-
Patent number: 10471075Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.Type: GrantFiled: September 20, 2017Date of Patent: November 12, 2019Assignee: AMAG PHARMACEUTICALS, INC.Inventors: Robert Birch, Michael J. Jozwiakowski
-
Patent number: 9844558Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.Type: GrantFiled: December 8, 2016Date of Patent: December 19, 2017Assignee: AMAG Pharmaceuticals, Inc.Inventors: Robert Birch, Michael J. Jozwiakowski
-
Patent number: 9555133Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.Type: GrantFiled: July 9, 2013Date of Patent: January 31, 2017Assignee: AMAG Pharmaceuticals, Inc.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Patent number: 8926947Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.Type: GrantFiled: June 11, 2014Date of Patent: January 6, 2015Assignee: AMAG Pharmaceuticals, Inc.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Patent number: 8591864Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.Type: GrantFiled: January 4, 2013Date of Patent: November 26, 2013Assignee: AMAG Pharmaceuticals, Inc.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Patent number: 8501158Abstract: Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.Type: GrantFiled: December 8, 2010Date of Patent: August 6, 2013Assignee: AMAG Pharmaceuticals, Inc.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Publication number: 20130121929Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Applicant: AMAG Pharmaceuticals, Inc.Inventor: AMAG Pharmaceuticals, Inc.
-
Publication number: 20120003160Abstract: Methods for performing macrophage-enhanced MRI, utilizing a macrophage imaging agent, in a single imaging session are provided. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle. One embodiment includes administering a macrophage imaging agent to the subject during an administration session then allowing a passage of time sufficient for accumulation of the agent in macrophages of the subject. Subsequently, in a single imaging session, a macrophage-enhanced magnetic resonance image is acquired to target macrophages and a different magnetic resonance image is acquired to target physiological phenomenon other than macrophages. Additional embodiments provide methods wherein the acquisition of a different magnetic resonance image is achieved by vascular-enhanced MRI protocols or perfusion-enhanced MRI protocols, or combinations thereof. Further embodiments provide methods for utilizing acquired images in assessment of treatment of disease.Type: ApplicationFiled: August 3, 2011Publication date: January 5, 2012Applicant: AMAG PHARMACEUTICALS, INC.Inventors: Gerald L. Wolf, Jerome M. Lewis
-
Publication number: 20110144054Abstract: Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.Type: ApplicationFiled: December 8, 2010Publication date: June 16, 2011Applicant: AMAG PHARMACEUTICALS, INC.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Patent number: 7871597Abstract: Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.Type: GrantFiled: April 9, 2003Date of Patent: January 18, 2011Assignee: AMAG Pharmaceuticals, Inc.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Patent number: 7553479Abstract: Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.Type: GrantFiled: March 11, 2003Date of Patent: June 30, 2009Assignee: AMAG Pharmaceuticals, Inc.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Publication number: 20090004113Abstract: Methods for assessing stage of cancer in a subject are provided, comprising administering a macrophage imaging agent to the subject, making a magnetic resonance image of regions of the subject's body at cancer risk, and using the image to assess macrophage density and displacement associated with any primary cancer or metastatic cancer in the subject, such density and displacement being indicative of neoplasia. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle and in particular embodiments, the macrophage imaging agent has a blood half-life sufficient to permit microphage trapping throughout the regions at cancer risk. Additional embodiments provide methods for assessing efficacy of an anticancer treatment in a subject, methods for determining frequency of follow-up MEMRI evaluation in a subject, methods for determining metastatic potential of cancer foci in a subject, and methods for determining prognosis of cancer in a subject.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: AMAG PHARMACEUTICALS, INC.Inventor: Gerald L. Wolf